Journal of Clinical Oncology
Articles in this Issue
Timing of postoperative chemoradiotherapy and survival outcomes in high-risk locally advanced head and neck squamous cell carcinoma: A supplementary analysis of JCOG1008.
6015 Background: For patients with post-operative high-risk locally advanced head and neck squamous cell carcinoma (LA-HNS...
Assessing a survival paradox in young-onset lung adenocarcinoma: Racial and ethnic disparities in SEER analysis.
e20114 Background: Survival outcomes in young adults with lung adenocarcinoma (LUAD) are poorly characterized, particularl...
Molecular profiling of colorectal cancer in a clinical diagnostic cohort: RAS/RAF alterations, microsatellite instability, and mismatch repair status.
e15644 Background: Molecular characterization of colorectal cancer (CRC) is essential for therapeutic stratification, part...
C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.
6083 Background: C-POST, a phase 3 trial (NCT03969004) in patients (pts) with high risk CSCC after surgery and radiotherap...
Clinical activity of REM-422, a MYB mRNA degrader, in recurrent/metastatic adenoid cystic carcinoma: Final results from the phase 1/2 dose-escalation cohort.
6009 Background: Adenoid cystic carcinoma (ACC) is a malignant neoplasm characterized by dysregulation of MYB, with the ma...
Overall survival for patients with pre-treated platinum-resistant ovarian cancer receiving gotistobart in combination with pembrolizumab.
5511 Background: Gotistobart, an investigational tumor microenvironment-selective Treg depletion antibody targeting CTLA-4...
Use of KMT2 family mutations to define a distinct epithelial-high, stromal-depleted, and interferon-active gene expression state in colorectal cancer.
3671 Background: The KMT2A–D (MLL1–4) family of H3K4 methyltransferases are critic...
A phase II trial evaluating liposomal irinotecan combined with capecitabine as second-line therapy for biliary tract cancer.
e16261 Background: Gemcitabine plus cisplatin remains the standard first-line therapy for advanced biliary tract cancers (...
Metastatic prostate cancer and heart failure hospitalizations: An intersection.
e17144 Background: Prostate cancer (PC) is the second most frequently diagnosed cancer in men. Those patients with metasta...
Association of inpatient outcomes with cannabis use disorder in head and neck cancer.
e18112 Background: Cannabis is the most commonly used illicit substance worldwide and has recently been identified as a ri...
Clinicopathological characteristics and targeted therapy response in <i>ALK</i> fusion–positive lung squamous cell carcinoma: A multicenter retrospective real-world study.
e20709 Background: Anaplastic lymphoma kinase (ALK) rearrangements are rare in lung squamous cell carcinoma (SqCC), and re...
Measurable residual disease (MRD) by circulating tumor (ct) DNA in patients (pt) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucel (liso-cel) in TRANSCEND FL.
7025 Background: ctDNA is a minimally invasive method for detecting MRD in various malignancies. MRD negativity (MRD...
Neutropenic diet (ND) versus liberalized diet (LD) in patients with cancer: A systematic review and meta-analysis.
e18574 Background: ND has historically been recommended to reduce infectious complications in cancer patients (pts). While...
Malnutrition and deaths associated with cancer in the United States.
e22579 Background: Patients with cancer have a heightened risk of malnutrition. The prevalence of malnutrition among cance...
Comparative efficacy of immune checkpoint inhibitor–anti-VEGF inhibitor combinations in non–small cell lung carcinoma: A network meta-analysis of randomized trials.
e20629 Background: Concomitant inhibition of the vascular endothelial growth factor (VEGF) pathway together with PD-1 or P...
Chemotherapy use among women < 50 years with node-negative early-stage hormone receptor–positive breast cancer with intermediate OncotypeDX 21-gene recurrence score: A National Cancer Database analysis.
e12546 Background: The Oncotype DX recurrence score (RS) multigene assay is widely-used to guide adjuvant chemotherapy (CT...
Association between physician characteristics and likelihood of caring for underserved patients with cancer.
1646 Background: Despite evidence that a diverse workforce may improve access to care for underserved patients, emerging p...
Impact of GLP-1 receptor agonists on outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter propensity-matched real-world analysis.
e16180 Background: First-line treatment of advanced unresectable or metastatic hepatocellular carcinoma (HCC) is now defin...
Influence of pelareorep on mutant KRAS-specific blood TIL clonal expansion.
2664 Background: Pelareorep (pela) is an intravenously delivered unmodified oncolytic reovirus that selectively infects ca...
New IMS/IMWG risk criteria by next-generation sequencing (NGS): Analysis of daratumumab benefit in both high- and standard-risk patients (pts) in the PERSEUS study.
7505 Background: IMS/IMWG recently proposed novel Consensus Genomic Staging (CGS) high-risk criteria for newly diagnosed m...
Phase IIa, open-label, multi-center study of the DNA polymerase theta inhibitor ART6043 administered orally in combination with olaparib to patients with HER2-negative breast cancer with a germline BRCA1/2 mutation (randomized expansion of study NCT05898399).
TPS1165 Background: Microhomology-mediated end joining (MMEJ) repair of DNA double-strand breaks is reliant on DNA polymer...
Real-world treatment patterns and clinical characteristics of patients with t(11;14)-positive multiple myeloma.
e23437 Background: Multiple myeloma (MM) patients harboring the t(11;14) translocation represent a distinct subtype with u...
Real-world characteristics, homologous recombination repair mutation (HRRm) testing, treatment patterns, and outcomes of patients with metastatic castration-sensitive prostate cancer (mCSPC) in the US community oncology setting.
5080 Background: Homologous recombination repair mutation (HRRm) testing is recommended by NCCN guidelines for metastatic...
Outcome of neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish nationwide population-based study (NEO-MEL).
9565 Background: Randomized trials have shown that neoadjuvant immune checkpoint inhibitor (ICI) improves outcomes compare...
Multimodal diffusion on low-rank approximation radiomic phenotypes with deep learning survival model for prediction of survival in post-operative GBM patients.
e14005 Background: Glioblastoma (GBM) exhibits substantial biological and imaging heterogeneity, resulting in variable pos...